A new-generation N/L-type calcium channel blocker leads to less activation of the renin-angiotensin system compared with conventional L type calcium channel blocker

Journal of Hypertension
Tadashi KonoshitaGenomic Disease Outcome Consortium Study Investigators

Abstract

Calcium channel blocker (CCB) is one of the most useful antihypertensive agents. However, the activation of the renin-angiotensin system (RAS) is an unfavorable characteristic. N-type calcium channel is thought to be involved in catecholamine's release. Accordingly, N/L-type CCB has a probability of less activation of the RAS. We substantiated the hypothesis that N/L-type CCB, cilnidipine, leads to less activation of the RAS compared with conventional L-type CCB, amlodipine. Randomized, cross-over study. Outpatient study. Participants were 110 hypertensive patients [male/female 46/64, age 66.3 ± 10.8 years, systolic blood pressure (SBP)/diastolic blood pressure (DBP) 161.8 ± 16.9/92.9 ± 12.4 mmHg, s-Cr 0.77 ± 0.32 mg/dl, plasma renin activity (PRA) 0.65 ± 0.63 ng/ml per h, angiotensin I (AngI) 70.5 ± 77.3 pg/ml, angiotensin II (AngII) 5.2 ± 3.9 pg/ml, plasma aldosterone concentration (PAC) 76.3 ± 35.9 pg/ml, urinary albumin excretion (UAE) 108.1 ± 284.2 mg/gCr]. Amlodipine besilate or cilnidipine was administered for 12 weeks in a cross-over manner as a monotherapy with an intention-to-treat fashion by titrating doses. Final doses of amlodipine besilate and cilnidipine were 6.6 ± 2.7 and 13.7 ± 5.1 mg/day, respectively. Changes...Continue Reading

References

Apr 25, 2000·Neuron·E A ErtelW A Catterall
Oct 14, 2000·Annual Review of Cell and Developmental Biology·W A Catterall
Feb 6, 2003·Journal of Hypertension·Sébastien FuchsFlorence Pinet
May 20, 2003·Kidney International·Piero RuggenentiUNKNOWN GISEN Group Investigators
Oct 29, 2003·Circulation·Mark J SarnakUNKNOWN American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology,
Sep 16, 2004·Journal of Cellular Biochemistry·Tadashi KonoshitaIsamu Miyamori
Apr 25, 2007·Journal of Cellular Biochemistry·Tadashi KonoshitaIsamu Miyamori
Jul 10, 2007·Journal of Diabetes and Its Complications·Tomomi FujisawaToshio Ogihara
Sep 22, 2007·Journal of Hypertension·Satoshi MorimotoToshiji Iwasaka
Oct 19, 2007·Kidney International·T FujitaUNKNOWN Cilnidipine versus Amlodipine Randomised Trial for Evaluation in Renal Desease(CARTER) Study Investigators
Apr 24, 2009·Clinical and Experimental Hypertension : CHE·Takuya KishiKenji Sunagawa
Jun 11, 2009·Diabetes Care·Tadashi KonoshitaUNKNOWN Genomic Disease Outcome Consortium (G-DOC) Study Investigators

❮ Previous
Next ❯

Citations

Jun 9, 2011·Clinical and Experimental Hypertension : CHE·Hiroaki MatsuokaUNKNOWN SAKURA Trial Investigators
Jun 7, 2011·Journal of the American Society of Hypertension : JASH·Sumito NaritaShin-ichi Ando
Nov 25, 2011·International Journal of Cardiology·Tadashi KonoshitaUNKNOWN Genomic Disease Outcome Consortium (G-DOC) Study Investigators
Feb 18, 2012·Diabetes Research and Clinical Practice·Shinya FukumotoUNKNOWN Cilnidipine vs L-type calcium channel blockers Evaluation of Antihypertensive Renoprotective Effects in Diabetic patients (C
Sep 15, 2015·PloS One·Yasukazu MakinoUNKNOWN Genomic Disease Outcome Consortium (G-DOC) Study Investigators
Feb 17, 2018·Hypertension Research : Official Journal of the Japanese Society of Hypertension·Satoko NozatoHiromi Rakugi
Jun 3, 2011·Hypertension Research : Official Journal of the Japanese Society of Hypertension·En Yin LaiRuisheng Liu
Sep 12, 2014·Hypertension Research : Official Journal of the Japanese Society of Hypertension·Kai NagasawaKohzo Nagata
Nov 17, 2012·Hypertension Research : Official Journal of the Japanese Society of Hypertension·Takashi YasudaUNKNOWN KVT Study Group
Jul 19, 2013·Hypertension Research : Official Journal of the Japanese Society of Hypertension·Atsuhisa Sato, Seiichi Fukuda
Jul 29, 2011·Hypertension Research : Official Journal of the Japanese Society of Hypertension·Naoki NakagawaUNKNOWN NICE-Combi Study Group
Nov 14, 2019·Cardiovascular Toxicology·Zeinab M AwwadAiman S El-Khatib
Jan 18, 2013·American Journal of Physiology. Renal Physiology·Keiichiro MishimaYoshihisa Nojima
Aug 16, 2016·Bioscience Reports·Tadashi KonoshitaUNKNOWN Genomic Disease Outcome Consortium (G-DOC) Study Investigators
Sep 7, 2021·American Journal of Physiology. Renal Physiology·Kyle H Moore, John S Clemmer
Nov 9, 2021·Clinical and Experimental Nephrology·Shoko OhnoHideki Yokoi

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.